Previous 10 | Next 10 |
First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South America PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-sta...
Silicon Valley luminaries, led by Apple alumnus and NeXT Computer co-founder Rich Page, to support the company’s technology development, data and analytics, and consumer engagement strategy PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified...
Company conference call and webcast at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 202...
Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the ...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, ...
Lucid Diagnostics' (LUCD -4.7%) unit LucidDx Labs acquired certain licenses and other related assets from ResearchDx to operate its own new CLIA-certified, CAP-accredited clinical laboratory located in Lake Forest, California. Lucid — which is a majority-owned subsidiary of P...
New wholly owned Lucid subsidiary now performing EsoGuard ® Esophageal DNA Test in its own new state-of-the-art CLIA-certified, CAP-accredited clinical laboratory Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention...
PAVmed (NASDAQ:PAVM) appointed Shaun O'Neil as EVP & COO, overseeing diverse corporate operations and commercial activities across the company and its subsidiaries. Mr. O’Neil has served as the company's Chief Commercial Officer and EVP, Business Development since joining...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appoin...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) , today announced the a...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...